Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Sandy

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2017
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistanceTerry D Crawford, Steffan Vartanian, Alexandre Côté, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Journal of Medicinal Chemistry|August 5, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1Alexander M Taylor, Chris Bailey, Lisa D Belmont, et al.
ACS Medicinal Chemistry Letters|July 26, 2017
GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)Terry D Crawford, James E Audia, Steve Bellon, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
The Journal of Biological Chemistry|April 9, 2016
Regulatory T Cell Modulation by CBP/EP300 Bromodomain InhibitionSrimoyee Ghosh, Alexander Taylor, Melissa Chin, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2017
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistanceTerry D Crawford, Steffan Vartanian, Alexandre Côté, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Journal of Medicinal Chemistry|August 5, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1Alexander M Taylor, Chris Bailey, Lisa D Belmont, et al.
ACS Medicinal Chemistry Letters|July 26, 2017
GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2)Terry D Crawford, James E Audia, Steve Bellon, et al.
Nature|October 23, 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1David A Barbie, Pablo Tamayo, Jesse S Boehm, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
The Journal of Biological Chemistry|April 9, 2016
Regulatory T Cell Modulation by CBP/EP300 Bromodomain InhibitionSrimoyee Ghosh, Alexander Taylor, Melissa Chin, et al.
Pageof 3